Tonix appoints former EVP James Hunter to Board; 7,740 option grant at $34.54

Tonix Pharmaceuticals Holding Corp.

Appointment effective June 12, 2025; Hunter served as EVP Commercial from June 2023 to Dec 2024.
Received 7,740 stock options at $34.54, vesting at 2026 annual shareholder meeting.
Hunter led launch of Tonix Medicines and migraine asset acquisitions Zembrace and Tosymra.
Board addition strengthens commercial expertise ahead of potential TNX-102 SL fibromyalgia launch; PDUFA Aug 15, 2025.
Not independent under NASDAQ standards due to prior consulting and employment compensation.

item 5.02item 8.01item 9.01

Executive movements

Appointed

James Hunter

member of the Board

TNXP · Tonix Pharmaceuticals Holding Corp.

Effective: 2025-06-12
Filed: Jun 13, 2025 23:59 UTC

appointed James Hunter as a member of the Board

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.